Brainstorm Cell Therapeutics Newsroom

Maxim Group Maintains Brainstorm Cell Therapeutics(BCLI.US) With Buy Rating, Maintains Target Price $2

Moomoo NewsAug 15 13:31 ET

Buy Rating Affirmed for Brainstorm Cell Therapeutics Amid Strategic Advances and Robust Financials

TipRanksAug 15 12:39 ET

Optimistic Buy Rating for Brainstorm Cell Therapeutics as NurOwn Advances Into Enhanced Phase 3b ALS Trial

TipRanksJul 12 07:37 ET

Brainstorm Cell Analyst Ratings

BenzingaJul 11 09:06 ET

Brainstorm Cell Analyst Ratings

BenzingaSep 28, 2023 10:13 ET

Brainstorm Cell Therapeutics (BCLI) Receives a Buy From Maxim Group

TipRanksAug 15, 2023 12:35 ET

Brainstorm Cell Therapeutics (BCLI) Receives a Buy From Maxim Group

TipRanksJun 7, 2023 13:25 ET

Maxim Group Adjusts Price Target on Brainstorm Cell Therapeutics to $10 From $5, Maintains Buy Rating

MT NewswiresMar 31, 2023 09:14 ET

Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Brainstorm Cell Therapeutics (BCLI) and Agilon Health (AGL)

TipRanksMar 29, 2023 08:21 ET

Brainstorm Cell Therapeutics (BCLI) Receives a Buy From Maxim Group

TipRanksJan 11, 2023 14:50 ET

Maxim Group Remains a Buy on Brainstorm Cell Therapeutics (BCLI)

TipRanksSep 16, 2022 12:55 ET

Brainstorm Cell Therapeutics (BCLI) Receives a Buy From Maxim Group

TipRanksAug 16, 2022 12:30 ET